Endometrial cancer after endometrial ablation: a systematic review

Tamara J Oderkerk,1,2 Mileen R D van de Kar,1 Karlijn M C Cornel,3 Marlies Y Bongers,1,2 Peggy M A J Geornini1

ABSTRACT

Objective To investigate whether a previously performed endometrial ablation is associated with the development and diagnosis of endometrial cancer.

Methods First, a systematic review was performed of the articles reporting the incidence of endometrial cancer in patients treated with endometrial ablation. Second, a systematic review was performed to identify all individual cases of endometrial cancer after ablation to evaluate presenting symptoms, diagnostic work-up, potential risk factors, and the type and stage of the endometrial cancer. A systematic search was performed, using Medline, EMBASE, and the Cochrane Library databases, from inception through February 24, 2022.

Results Based on 11 included studies, the incidence of endometrial cancer in a population of 29,102 patients with a prior endometrial ablation ranged from 0.0% to 1.6%. A total of 38 cases of endometrial cancer after ablation were identified. In 71% of cases (17 of 24 cases), vaginal bleeding was the first presenting symptom. With transvaginal ultrasound it was possible to identify and measure the endometrial thickness in eight cases. Endometrium sampling was successful in 16 of 18 described cases (89%). In 18 of 20 cases (90%) pathologic examination showed early-stage endometrioid adenocarcinoma (International Federation of Gynecology and Obstetrics stage I).

Conclusion Previous endometrial ablation is not associated with the development of endometrial cancer. Diagnostic work-up is not impeded by previous endometrial ablation. In addition, endometrial cancers after endometrial ablation are not detected at an advanced stage.

INTRODUCTION

Endometrial ablation as a treatment option for heavy menstrual bleeding has gained popularity since techniques have improved over the last two decades.1,2 However, due to amenorrheic menstrual patterns and the development of intrauterine and intracervical adhesions, questions have risen about difficulties of diagnosing endometrial pathology after ablation. There is a particular concern that diagnosis of endometrial cancer may be missed or recognized too late, because post-menopausal bleeding could be absent or delayed.3 Endometrial cancer is the most common gynecologic malignancy worldwide, with a yearly increasing mean incidence of 3.1% lifetime risk in the general population in 2021.4 More than 90% of the patients present with post-menopausal bleeding or heavy or irregular menstrual bleeding.5 Due to the presentation of unexpected vaginal bleeding, endometrial cancer is diagnosed at an early stage of disease in around 75% of cases, resulting in high survival rates.6,7

Transvaginal ultrasonography is mostly used as diagnostic tool to visualize the endometrium thickness and regularity. Generally, when the total endometrium thickness is more than 3 to 4 mm or the endometrial profile is of irregular aspect, the Royal College of Obstetricians and Gynecologists guideline recommends endometrium sampling to examine the microscopic aspect of the endometrium.8–10 It is unclear whether a previously performed endometrial ablation has a negative effect on the diagnostic work-up of endometrial cancer as literature on the correlation between endometrial cancer after ablation is limited.11,12 A potential problem could be the decrease in sensitivity of ultrasound features after ablation because post-menopausal bleeding could be absent or delayed.3
Original research

Furthermore, difficulties in endometrial sampling due to intrauterine adhesions might be expected.3 13–16

The aim of this systematic review is to investigate whether a previous performed endometrial ablation is associated with the development and diagnosis of endometrial cancer. This review concentrated on two objectives. First, a systematic review of studies describing the incidence of endometrial cancer after endometrial ablation. Second, an evaluation of all cases as described in the literature on endometrial cancer after ablation to evaluate first symptoms, diagnostic work-up, potential risk factors, and the type and stage of endometrial cancer.

METHODS

The Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) guidelines were used to report our systematic review.17 The protocol was registered in PROSPERO, international prospective register of systematic reviews (ID: CRD42020175973).18 In accordance with the journal’s guidelines, we will provide our data for independent analysis by a selected team for the purposes of additional data analysis or for reproducibility of this study.

Database Search

A broad systematic search was performed, to answer both research questions, using Medline, EMBASE, and the Cochrane Library databases from inception through February 24, 2022, aided by an information and database analyst. Searching with Medline keywords: endometrial ablation techniques, endometrial neoplasms/carcinoma/tumor, cancer/carcinoma of the endometrium or endometrium carcinoma. A complete overview of the search can be found in online supplemental file 1.

Incidence of Endometrial Cancer after Endometrial Ablation

Eligibility Criteria

For the systematic review all original articles reporting the incidence of endometrial cancer in a population of patients with a prior endometrial ablation were included. No distinction between endometrial ablation techniques was made. Exclusion criteria were publications in which endometrial ablation was performed for indications other than heavy menstrual bleeding, and articles or cases were excluded if endometrial cancer was diagnosed before or during the ablation. Publications were also excluded if no full text was available, or the article could not be translated to English.

Outcome

The primary outcome was to establish the incidence of endometrial cancer in patients previously treated with endometrial ablation for heavy menstrual bleeding.

Selection of Eligible Articles

All publications were imported in the program Rayyan QCRI, and duplicates were removed.19 Two independent reviewers (TJO and MRDK) assessed each abstract and selected full text articles matching the inclusion and exclusion criteria. Any disagreement was solved by discussion or by means of a third reviewer (KMCC).

Data Extraction

The data were systematically collected in a data extraction sheet with article information (name of author and year of publication), study design, ablation techniques, range or mean/median follow-up, number of participants, and number of cases of endometrial cancer identified.

Statistical Analysis

We used descriptive statistics to report data on incidence of endometrial cancer in patients with a prior endometrial ablation.

Risk of Bias Assessment

The risk of bias for the included cohort studies was assessed using the ROBINS-I tool. For randomized controlled trials, the risk of bias was assessed using the revised Cochrane risk-of-bias tool for randomized trials (RoB 2).20 21 Both were assessed by two individual reviewers (TJO and MRDK). The studies were rated low risk of bias, moderate risk of bias, high risk of bias, or unclear. Any disagreement on the classification of risk of bias was resolved by discussion or by means of a third reviewer (KMCC).

Reported Case Studies

Eligibility Criteria

Articles describing individual cases of endometrial cancer after endometrial ablation were included. Exclusion criteria were the same as described above.

Outcomes and Data Extraction

We reviewed all cases reporting endometrial cancer in patients treated with endometrial ablation for heavy menstrual bleeding and reviewed data on presenting symptoms, the diagnostic work-up, and type and stage of cancer. Also, article information (name of author and year of publication), potential risk factors, ablation technique, age at time of endometrial cancer diagnosis, time from ablation to cancer diagnosis, and type of treatment were collected.

RESULTS

Included Studies

Our literature search yielded in total 890 publications from Medline database (n=184), Cochrane Library (n=4) and EMBASE database (n=702). After duplicates were removed, 734 publications were left for assessment. Eventually, 11 articles were included in the systematic review on incidence of endometrial cancer after endometrial ablation; nine retrospective studies, one prospective cohort study, and one randomized controlled trial.3 13–16 22–27 Twenty-four articles were included describing a total of 38 individual cases of endometrial cancer after ablation.3 11 13–15 22–25 27–41 The flow diagram for study selection is shown in Figure 1.

Incidence of Endometrial Cancer after Endometrial Ablation

According to the incidence data from 10 cohort studies and one randomized controlled trial, 29102 patients after endometrial ablation were followed up for a period until 25 years after ablation (Table 1).3 13–16 22–27 The incidence of endometrial cancer after endometrial ablation varied from 0.0% to 1.6%.

Reported Case studies

From our extensive search, 24 articles were included describing single or multiple cases of endometrial cancer after ablation.3 11 13–15 22–25 27–41 In total 38 cases were described. A summary
of these included cases is shown in Table 2, and a detailed elaboration of the cases is provided in online supplemental file 2.

In 17 of 24 cases (71%) vaginal bleeding was the mean reason for patients to consult the gynecologist and five patients (21%) presented with pelvic pain. The discovery of two cases (8%) of asymptomatic endometrial adenocarcinoma was unexpected. The first patient had a hysterectomy as part of prolapse surgery, and the other had an ultrasound as part of a study by Morelli et al investigating ultrasound images in patients who had endometrial ablation. In nine cases the assessment of the endometrium was performed using transvaginal ultrasonography. In eight cases a thickened endometrium more than 7 mm, or irregular endometrium/myometrium, was described, with consequently a biopsy. In the case of Morelli et al, the ultrasound image showed an intracavitary collection of fluid, thus hysteroscopy and biopsy were performed.

Endometrial sampling was performed using pipelle or hysteroscopic biopsy in 18 of the 21 cases and was successful in 16 (89%) cases. In three cases endometrial biopsy initially failed due to intrauterine adhesions. In one of these cases, biopsy was eventually successful using a smaller hysteroscope and hysteroscopic surgery with partial removal of intracervical and intrauterine adhesions. In the remaining two cases a hysterectomy was performed to confirm the diagnosis.

The type and stage of endometrial cancer is known for 53% of the cases (20 cases). At the time of diagnosis 90% (n=18) of cases showed stage I endometrioid-type adenocarcinoma according to the International Federation of Gynecology and Obstetrics (FIGO), and one case showed FIGO stage II/III endometrial adenocarcinoma. In one case histology showed a villoglandular adenocarcinoma. In 15 cases (71%) pathology showed well-differentiated endometrial adenocarcinoma and in six cases (29%) pathology revealed moderately or poorly differentiated endometrial adenocarcinoma.

### DISCUSSION

#### Summary of Main Results

Based on 11 studies, the incidence of endometrial cancer among patients with a history of endometrial ablation varies from 0.0% to 1.6%. Thirty-eight cases of endometrial cancer after ablation are described in the literature. In 71% of the cases, vaginal bleeding was the presenting symptom of the disease. Endometrial sampling was successful in 89% of cases, and in 90% of cases pathologic examination showed early-stage endometrioid adenocarcinoma (FIGO stage I).

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Study design</th>
<th>Population (N)</th>
<th>Number of EC cases (N)</th>
<th>Follow-up time in years, mean/median† (range)</th>
<th>Incidence (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bhattacharya et al 2011</td>
<td>Retrospective cohort study</td>
<td>11299</td>
<td>2</td>
<td>6.2† (2.7–10.8)</td>
<td>0.02</td>
</tr>
<tr>
<td>Cooper et al 2005</td>
<td>Randomized controlled trial</td>
<td>263</td>
<td>1</td>
<td>NA (5.2–7)</td>
<td>0.38</td>
</tr>
<tr>
<td>Dood et al 2014</td>
<td>Retrospective cohort study</td>
<td>4776</td>
<td>3</td>
<td>5.5† (IQR 3.2–8)</td>
<td>0.06</td>
</tr>
<tr>
<td>Gaia et al 2007</td>
<td>Retrospective cohort study</td>
<td>3769</td>
<td>1</td>
<td>NA (0–11)</td>
<td>0.03</td>
</tr>
<tr>
<td>Kalampokas et al 2018</td>
<td>Retrospective observational study</td>
<td>901</td>
<td>2</td>
<td>NA18–25</td>
<td>0.22</td>
</tr>
<tr>
<td>Krogh et al 2009</td>
<td>Retrospective cohort study</td>
<td>367</td>
<td>3</td>
<td>11.1* (8.1–14.6)</td>
<td>0.82</td>
</tr>
<tr>
<td>Morelli et al 2015</td>
<td>Retrospective observational study</td>
<td>63</td>
<td>1</td>
<td>NA (0–14)</td>
<td>1.59</td>
</tr>
<tr>
<td>Neuwirth et al 2004</td>
<td>Retrospective cohort study</td>
<td>466</td>
<td>2</td>
<td>NA24</td>
<td>0.43</td>
</tr>
<tr>
<td>Panoskaltsis et al 2002</td>
<td>Prospective observational study</td>
<td>193</td>
<td>0</td>
<td>6† (IQR 4–7)</td>
<td>0.0</td>
</tr>
<tr>
<td>Singh et al 2016</td>
<td>Retrospective observational study</td>
<td>1521</td>
<td>0</td>
<td>10†3–17</td>
<td>0.0</td>
</tr>
<tr>
<td>Soi et al 2017</td>
<td>Retrospective cohort study</td>
<td>5484</td>
<td>3</td>
<td>7.3* (0–18)</td>
<td>0.05</td>
</tr>
</tbody>
</table>

*Mean follow-up. †Median follow-up.
EC, endometrial carcinoma; IQR, interquartile range.

---

Table 2  Summary of endometrial cancer cases after endometrial ablation (n=38)

<table>
<thead>
<tr>
<th></th>
<th>Number of endometrial carcinoma cases, N</th>
<th>Percentage of endometrial carcinoma cases/total (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total cases</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>Ablation methods</td>
<td>32</td>
<td></td>
</tr>
<tr>
<td>Resectoscope</td>
<td>9</td>
<td>28</td>
</tr>
<tr>
<td>Roller-ball</td>
<td>5</td>
<td>16</td>
</tr>
<tr>
<td>(not specified) Hysteroscopic</td>
<td>6</td>
<td>19</td>
</tr>
<tr>
<td>Endometrial ablation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(not specified) Non-hysteroscopic</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Endometrial ablation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thermal balloon</td>
<td>4</td>
<td>13</td>
</tr>
<tr>
<td>Radio-frequent endometrial ablation</td>
<td>4</td>
<td>13</td>
</tr>
<tr>
<td>Mix of methods</td>
<td>3</td>
<td>9</td>
</tr>
<tr>
<td>Risk factors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Morbid) obesity</td>
<td>13</td>
<td>65</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>4</td>
<td>20</td>
</tr>
<tr>
<td>Hypertension</td>
<td>6</td>
<td>30</td>
</tr>
<tr>
<td>History of cancer</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>Nulliparity</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Estrogen/hormone replacement therapy</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>Polycystic ovary syndrome</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>None</td>
<td>4</td>
<td>20</td>
</tr>
<tr>
<td>Symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vaginal bleeding</td>
<td>17</td>
<td>71</td>
</tr>
<tr>
<td>Pelvic pain</td>
<td>5</td>
<td>21</td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>Diagnostic tools</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pelvic examination</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>Ultrasound</td>
<td>9</td>
<td>43</td>
</tr>
<tr>
<td>Hysteroscopy</td>
<td>9</td>
<td>43</td>
</tr>
<tr>
<td>Hydrosonography</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Successful endometrial biopsy</td>
<td>16</td>
<td>76</td>
</tr>
<tr>
<td>Unsuccessful endometrial biopsy</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>Cervix cytology</td>
<td>2</td>
<td>10</td>
</tr>
<tr>
<td>CT scan</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Type and stage of cancer (FIGO)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrioid adenocarcinoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>stage I</td>
<td>18</td>
<td>90</td>
</tr>
<tr>
<td>Endometrioid adenocarcinoma</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>stage II/III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endometrioid adenocarcinoma</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>stage III</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vulloglandular adenocarcinoma</td>
<td>1</td>
<td>5</td>
</tr>
</tbody>
</table>

*The sum of these percentages is not 100%, due to multi possible answers.

FIGO, International Federation of Gynecology and Obstetrics.

Results in the Context of Published Literature

Incidence of Endometrial Carcinoma after Endometrial Ablation

Based on the results of this review the incidence of endometrial cancer varies from 0.0% to 1.6% in patients with a prior endometrial ablation. The lifetime incidence of endometrial carcinoma in the general population is 3.1%.4 The available literature is limited and nine out of 11 included studies had a follow-up period of less than 15 years. As most patients receive endometrial ablation when they are pre-menopausal or peri-menopausal, a follow-up period of at least 15 to 20 years is necessary to detect the majority of endometrial cancers, since the peak incidence of endometrial cancer in the general population is at around 61 years old.42–44 The prospective study of Kalampokas et al14 studied patients (n=901) with endometrial ablation with a follow-up period of 18 to 25 years after ablation and found an incidence of endometrial carcinoma of 0.2%.14 Also, in the study of Neuwirth et al,3 with a follow-up duration of up to 24 years, an incidence of 0.4% endometrial cancer after ablation was found.5 These results still confirm our finding of no increased risk for the development of endometrial cancer after ablation.

Nevertheless, confounding is a problem in the comparison of endometrial cancer between patients treated for heavy menstrual bleeding and the general population. Hypothetically, these patients have an increased risk of developing endometrial cancer since anovulatory bleeding and hyperplasia (common causes of heavy menstrual bleeding) coincide with obesity, which is associated with an increased risk of endometrial cancer. However, clear evidence from literature is lacking. In the study of Dood et al, confounding is partly addressed by comparing patients with heavy menstrual bleeding treated with endometrial ablation and patients receiving medical management. No increased risk of endometrial carcinoma was found, with 0.06% in the endometrial ablation group versus 0.26% in the medical management group. However, the median follow-up duration in both groups was relatively short, 5.5 and 4 years, respectively.13 More long-term data are needed.

Reported Case Studies of Endometrial Carcinoma after Endometrial Ablation

There are only limited data available on endometrial cancer after endometrial ablation, as we identified only 38 cases in our systematic literature search. It is likely that there is under-reporting of the cases. Moreover, in 11 out of 38 cases, information on time between ablation and cancer diagnosis was limited.

Unexpected vaginal bleeding is of substantial importance to diagnose endometrial cancer at an early stage. In this review, 74% of the patients presented with unexpected vaginal bleeding after treatment with endometrial ablation, which is lower than 90% in the general population.5 A total of 22% of patients presented with pelvic pain. All cases were diagnosed at early stage of disease. The symptoms at presentation of endometrial cancer appear to be consistent with those of the general population. Transvaginal ultrasoundography after endometrial ablation can be inconclusive, because of the total destruction of the endometrial basic layer, which impairs endometrial growth.45 46 In this review the findings of transvaginal sonography are described in only eight cases. However, in a study of Arora et al, 71% of patients treated with endometrial ablation appeared to have a measurable endometrium on transvaginal sonography.31
Moreover, there are questions on the accessibility of the uterine cavity after treatment with endometrial ablation due to the presence of intrauterine adhesions, resulting in difficult endometrial sampling. However, the results of this review do not confirm a reduced success rate of endometrial sampling, as 89% of the cases were diagnosed with endometrial sampling using pipelle and/or hysteroscopic biopsies. The study of Arora confirms these results, as in their study endometrial biopsies failed in only 8% (12/153) of the cases, and a hysteroscopic sampling succeeded in 94% of cases. In addition, MacMahon et al (2018) described six cases in which access to the uterine cavity was difficult. Nevertheless, they all succeeded in obtaining a biopsy by hysteroscopy. All pathological findings were detected.

Ninety per cent of cases were diagnosed as FIGO stage I endometrioid adenocarcinoma compared with 75% in the general population. This suggests that diagnosing endometrial cancer does not seem to be delayed in patients with endometrial ablation.

Strengths and weaknesses
This is the first systematic review reporting all described endometrial cancers in patients treated with endometrial ablation for heavy menstrual bleeding. An extensive search of the literature was performed to detect all reported cases on endometrial cancer in patients who were treated with endometrial ablation for the indication of heavy menstrual bleeding. The latest review on this subject of Bardawil et al found 37 cases, including six cases of patients treated with endometrial ablation as treatment for postmenopausal bleeding, four cases of patients diagnosed with endometrial cancer at the time of ablation, and two cases that did not contain any clinical information. We have excluded those cases in this review and thus found 13 new cases, providing a more representative impression of the cohort patients with endometrial carcinoma after ablation.

Limitations of this systematic review are the small number of available prospective studies and randomized controlled trials, causing a risk of publication and selection bias. The use of different types of ablation techniques in the included studies could possibly result in bias of the outcome. Also, due to the wide range of follow-up times among studies (0 to 25 years), calculation of the mean incidence cannot be expressed for a specific time, and a lifetime incidence cannot be calculated. The data could not be pooled, because of various methodological issues—namely, variation in population sizes, different types of study design, and most importantly, the differing follow-up times among studies, which affect the occurrence of cancer.

All 11 included studies in the systematic review scored a moderate to high risk of bias. Specifically, bias due to confounding was of risk for our primary outcome measure due to the absence of information on risk factors for endometrial carcinoma or when endometrial ablation was not specified as treatment for heavy menstrual bleeding. In addition, three studies scored a serious risk of bias in participant selection due to an unrepresentative group of patients included in the analyses. The bias table can be found in online supplemental file 3. Moreover, 11 of the 38 cases found in literature (28.9%) had missing data, which further increased the risk of (reporting and selection) bias.

Implications for Practice and Future Research
According to our results, treatment with endometrial ablation does not appear to increase the risk of endometrial cancer. Instead, these results suggest a reduced risk of endometrial carcinoma. Some studies argue that endometrial ablation may be a protective factor for developing endometrial cancer. Hypothetically a reduction in the amount of the endometrium tissue caused by endometrial destruction would decrease the chance of developing a malignancy. However, owing to limited available data, until now evidence to support this hypothesis is not sufficiently strong. Research with proper control groups (patients with heavy menstrual bleeding) after endometrial ablation including long term follow-up is recommended to improve our understanding of the relation between endometrial ablation and the development of endometrial cancer.

CONCLUSIONS
Based on 11 cohort studies, we can conclude that the incidence of endometrial cancer does not seem to increase in patients with a history of endometrial ablation. There appears to be no delay in the diagnosis of endometrial cancer after endometrial ablation, as diagnostic management with endometrial sampling does not seem to be a barrier after ablation. In addition, endometrial cancers after endometrial ablation do not appear to be detected at a more advanced stage of the disease.

Author affiliations
1Department of Obstetrics and Gynecology, Máxima Medical Centre Location Veldhoven, Veldhoven, The Netherlands
2School for Oncology and Reproduction (GROW), Maastricht University, Maastricht, Limburg, The Netherlands
3Department of Obstetrics and Gynecology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada

Contributors TJO, MRDK, KMCC, PMG, and MYB were involved in conception and design of the study. TJO and MRDK drafted the first manuscript. All authors edited the manuscript and read and approved the submitted version. TJO is guarantor.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests MYB reports financial relationships with Gynesonics (device reduction in clinical trials), outside the submitted work. MYB is a member of the advisory board of Hologic. The remaining authors declare no conflicts of interest.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iD
Tamara J Oderkerk http://orcid.org/0000-0003-2307-0338
Original research

REFERENCES


